+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of enpatoran in adults with active cutaneous manifestations of lupus erythematosus, with or without systemic disease, in this global, multicenter Phase 3 study. The study aims to assess enpatorans effect over 24 weeks compared to a placebo, focusing on skin disease activity and safety outcomes. Participants include those diagnosed with discoid, subacute cutaneous lupus, or active acute cutaneous lupus alongside systemic lupus erythematosus. Participants will receive either enpatoran tablets or matching placebo tablets orally twice daily for 24 weeks Day 1 to Day 168, alongside investigator-recommended standard of care. The study includes scheduled visits every 4 weeks, with a telehealth visit at Week 2. The intervention is administered as film-coated tablets, and the treatment period lasts for 24 weeks within an overall study duration of up to 35 weeks. During the study, participants will be monitored through regular visits every 4 weeks to assess skin disease using the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other clinical measurements. Researchers will evaluate skin improvement, lupus disease activity, adverse events, laboratory parameters, and corticosteroid use. Safety and treatment effects will be closely followed during and after the treatment period, with the primary outcome assessed at Week 24.

Age: 18Years - 75YearsAll GendersPhase 3
74 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
C

Actively Recruiting

Researchers are evaluating the effects of benfotiamine compared to vitamin B1-6-12 in adults with diabetic peripheral neuropathy. This condition causes sensory neuropathy symptoms, numbness, and pain, and the study aims to find out if benfotiamine reduces these symptoms more effectively than vitamin B1-6-12. The trial is a phase 4, randomized, double-blind study designed to compare these treatments over 12 weeks. Participants will be randomly assigned to one of two groups one receiving benfotiamine 150 mg twice daily, and the other receiving a combined vitamin B1 100 mg, B6 5 mg, and B12 65 mcg pill twice daily. Both treatments are given orally for three months and are made to look identical to keep the study blinded. Before enrollment, participants will be screened for vitamin B12 deficiency, and those with low levels will not be eligible. During the study, participants will have two in-person clinic visits at the start and end of the 12-week treatment period, along with two telephone follow-ups. They will continue their usual medications as long as no new neuropathic pain treatments are started and existing doses remain stable. Researchers will assess changes in neuropathy symptoms, numbness, and pain over the course of treatment using standardized symptom scores and patient impressions of change.

Age: 18Years +All GendersPhase 4
1 location